MedKoo product information:

 Lanreotide acetate

Lanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide. Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration (FDA) on August 30, 2007.

Lanreotide is available in two formulations: a sustained release formulation (sold under the trade name Somatuline LA), which is injected intramuscularly every ten or fourteen days,[4] and an extended release formulation (UK trade name Somatuline Autogel, or Somatuline Depot in the U.S.), which is administered subcutaneously once a month.

Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas. In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma, a rare tumor of the pituitary gland which secretes TSH. Interestingly, lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogues, is being studied as a possible general antitumor agent.

  1: Molina-Trinidad EM, de Murphy CA, Jung-Cook H, Stack EM, Pedraza-Lopez M, Morales-Marquez JL, Serrano GV. Therapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats. J Pharm Pharmacol. 2010 Apr;62(4):456-61. PubMed PMID: 20604834.

2: Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM; Pasireotide Acromegaly Study Group. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010 Jun;95(6):2781-9. Epub 2010 Apr 21. PubMed PMID: 20410233.

3: Sesmilo G, Webb SM; Neuroendocrinology Group of the Spanish Society of Endocrinology and Nutrition. Twelve years of the Spanish acromegaly registry: a historical view of acromegaly management in Spain. Endocrinol Nutr. 2010 Feb;57(2):39-42. Epub 2010 Mar 1. PubMed PMID: 20189894.

4: Traub-Weidinger T, Von Guggenberg E, Dobrozemsky G, Kendler D, Eisterer W, Bale R, Putzer D, Gabriel M, Virgolini I. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography. Q J Nucl Med Mol Imaging. 2010 Feb;54(1):52-60. PubMed PMID: 20168286.

5: Bombardieri E, Coliva A, Maccauro M, Seregni E, Orunesu E, Chiti A, Lucignani G. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals. Q J Nucl Med Mol Imaging. 2010 Feb;54(1):3-15. PubMed PMID: 20168282.

6: Auriemma RS, Galdiero M, Grasso LF, Vitale P, Cozzolino A, Lombardi G, Colao A, Pivonello R. Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. Eur J Endocrinol. 2010 May;162(5):993-9. Epub 2010 Feb 15. PubMed PMID: 20156970.

7: Barabash R, Moreno-Suárez FG, Rodríguez L, Molina AM, Conejo-Mir J. [Nelson syndrome: a rare cause of generalized hyperpigmentation of the skin]. Actas Dermosifiliogr. 2010 Jan-Feb;101(1):76-80. Spanish. PubMed PMID: 20109395.

8: Mao ZG, Zhu YH, Tang HL, Wang DY, Zhou J, He DS, Lan H, Luo BN, Wang HJ. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol. 2010 Apr;162(4):661-6. Epub 2010 Jan 8. PubMed PMID: 20061334.

9: Lapeire LD, Tansens A, Lemmens GM, Van Belle SJ. Carcinoid encephalopathy: A single entity or a spectrum of different disorders? Acta Oncol. 2010;49(2):268-70. PubMed PMID: 20001498.

10: Bornschein J, Drozdov I, Malfertheiner P. Octreotide LAR: safety and tolerability issues. Expert Opin Drug Saf. 2009 Nov;8(6):755-68. Review. PubMed PMID: 19998528.

11: Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010 Jan 29;17(1):R53-73. Print 2010 Mar. Review. PubMed PMID: 19995807.

12: Beck-Peccoz P, Persani L, Mannavola D, Campi I. Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):597-606. Review. PubMed PMID: 19945025.

13: Ruscica M, Arvigo M, Gatto F, Dozio E, Feltrin D, Culler MD, Minuto F, Motta M, Ferone D, Magni P. Regulation of prostate cancer cell proliferation by somatostatin receptor activation. Mol Cell Endocrinol. 2010 Feb 5;315(1-2):254-62. Epub 2009 Nov 20. PubMed PMID: 19932151.

14: Ben Salem Hachmi L, Kammoun I, Bouzid C, Smida H, Nagi S, Turki Z, Ben Slama C. [Management of acromegaly in pregnant woman]. Ann Endocrinol (Paris). 2010 Feb;71(1):60-3. Epub 2009 Nov 18. French. PubMed PMID: 19926070.

15: Psaras T, Milian M, Hattermann V, Gallwitz B, Freiman T, Honegger J. Aftercare in patients with Cushing's disease and acromegaly: is there room for improvement? Acta Neurochir (Wien). 2010 Feb;152(2):271-8. Epub 2009 Nov 13. PubMed PMID: 19911113.

16: Borbath I, Leclercq IA, Sempoux C, Abarca-Quinones J, Desaeger C, Horsmans Y. Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Chem Biol Interact. 2010 Jan 5;183(1):238-48. Epub . PubMed PMID: 19874807.

17: Feelders RA, Hofland LJ, van Aken MO, Neggers SJ, Lamberts SW, de Herder WW, van der Lely AJ. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs. 2009 Nov 12;69(16):2207-26. doi: 10.2165/11318510-000000000-00000. Review. PubMed PMID: 19852525.

18: Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V, Liu NA, Culler M, Melmed S. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab. 2009 Nov;94(11):4342-50. Epub 2009 Oct 9. PubMed PMID: 19820006.

19: Pisarek H, Pawlikowski M, Kunert-Radek J, Radek M. Expression of somatostatin receptor subtypes in human pituitary adenomas -- immunohistochemical studies. Endokrynol Pol. 2009 Jul-Aug;60(4):240-51. PubMed PMID: 19753537.

20: Msaouel P, Galanis E, Koutsilieris M. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opin Investig Drugs. 2009 Sep;18(9):1297-316. Review. PubMed PMID: 19678799.

21: van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009 Nov;137(5):1661-8.e1-2. Epub 2009 Jul 29. PubMed PMID: 19646443.

22: Theodoropoulou M, Tichomirowa MA, Sievers C, Yassouridis A, Arzberger T, Hougrand O, Deprez M, Daly AF, Petrossians P, Pagotto U, Beckers A, Stalla GK. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. Int J Cancer. 2009 Nov 1;125(9):2122-6. PubMed PMID: 19637311.

23: Clemente Gallego D, Gómez Bueno M, Lucas Morante T. [Acromegalic myocardiopathy]. Endocrinol Nutr. 2009 Feb;56(2):96-8. Epub 2009 May 1. Spanish. PubMed PMID: 19627718.

24: Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab. 2009 Oct;94(10):3746-56. Epub 2009 Jul 21. PubMed PMID: 19622615.

25: Lombardi G, Minuto F, Tamburrano G, Ambrosio MR, Arnaldi G, Arosio M, Chiarini V, Cozzi R, Grottoli S, Mantero F, Bogazzi F, Terzolo M, Tita P, Boscani PF, Colao A. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest. 2009 Mar;32(3):202-9. PubMed PMID: 19542735.

26: Castinetti F, Saveanu A, Morange I, Brue T. Lanreotide for the treatment of acromegaly. Adv Ther. 2009 Jun;26(6):600-12. Epub 2009 Jun 16. Review. PubMed PMID: 19533047.

27: Ning S, Knox SJ, Harsh GR, Culler MD, Katznelson L. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells. Endocr Relat Cancer. 2009 Sep;16(3):1045-55. Epub 2009 Jun 15. PubMed PMID: 19528243.

28: Falhammar H. Cyclic ectopic Cushing's syndrome and somatostatin analogue treatment. N Z Med J. 2009 Apr 24;122(1294):92-5. PubMed PMID: 19465952.

29: Mitsogiannis IC, Skolarikos A, Deliveliotis C. Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC). Expert Opin Pharmacother. 2009 Feb;10(3):493-501. Review. PubMed PMID: 19191684.

30: Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg. 2009 Feb;96(2):175-84. PubMed PMID: 19160361.

31: Colao A, Auriemma RS, Rebora A, Galdiero M, Resmini E, Minuto F, Lombardi G, Pivonello R, Ferone D. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf). 2009 Aug;71(2):237-45. Epub 2008 Dec 15. PubMed PMID: 19094074.

32: Touloumis Z, Delis SG, Triantopoulou C, Giannakou N, Avgerinos C, Dervenis C. Primary hepatic carcinoid; a diagnostic dilemma: a case report. Cases J. 2008 Nov 17;1(1):314. PubMed PMID: 19014620; PubMed Central PMCID: PMC2596793.

33: Lamberts SW, Hofland LJ. Future treatment strategies of aggressive pituitary tumors. Pituitary. 2009;12(3):261-4. Review. PubMed PMID: 19003539; PubMed Central PMCID: PMC2712619.

34: Drutel A, Caron P, Archambeaud F. [New medical treatments in pituitary adenomas]. Ann Endocrinol (Paris). 2008 Sep;69 Suppl 1:S16-28. Review. French. PubMed PMID: 18954854.

35: Kanyinda-K JM, Samalin E, Sebah H, Gallix B, Ychou M. [Efficacy of prolonged-release somatostatin analog monotherapy in metastatic endocrine tumors]. Gastroenterol Clin Biol. 2008 Dec;32(12):989-91. Epub 2008 Oct 21. French. PubMed PMID: 18945567.

36: Scholz A, Wagner K, Welzel M, Remlinger F, Wiedenmann B, Siemeister G, Rosewicz S, Detjen KM. The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model. Gut. 2009 Feb;58(2):261-70. Epub 2008 Oct 1. PubMed PMID: 18829975.

37: Hogan MC, Torres VE. What the similarities of specific polycystic liver and kidney diseases can teach us about both. Nephrol News Issues. 2008 Aug;22(9):29-31. Review. PubMed PMID: 18778002.

38: van Keimpema L, de Man RA, Drenth JP. Somatostatin analogues reduce liver volume in polycystic liver disease. Gut. 2008 Sep;57(9):1338-9. PubMed PMID: 18719151.

39: Kapella M, Gana J, Decroisette E, Aubard Y. Para-aortic lymphocele treated with an injection of somatostatine analog (lanreotide). Eur J Obstet Gynecol Reprod Biol. 2008 Nov;141(1):89-90. Epub 2008 Aug 5. PubMed PMID: 18684551.

40: Grozinsky-Glasberg S, Kaltsas G, Gur C, Gal E, Thomas D, Fichman S, Alexandraki K, Barak D, Glaser B, Shimon I, Gross DJ. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol. 2008 Oct;159(4):475-82. Epub 2008 Jul 28. PubMed PMID: 18662970.

41: Saveanu A, Jaquet P. Somatostatin-dopamine ligands in the treatment of pituitary adenomas. Rev Endocr Metab Disord. 2009 Jun;10(2):83-90. Epub 2008 Jul 24. Review. PubMed PMID: 18651224.

42: Kidd M, Drozdov I, Joseph R, Pfragner R, Culler M, Modlin I. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer. 2008 Aug 15;113(4):690-700. PubMed PMID: 18618499; PubMed Central PMCID: PMC2574930.

43: Hussar DA. New drugs08, part 2. Nursing. 2008 Jul;38(7):41-8; quiz 49. PubMed PMID: 18580663.

44: Hansen CP, Knigge U. [Biotherapy of neuroendocrine tumours of the gastrointestinal tract and pancreas]. Ugeskr Laeger. 2008 Jun 9;170(24):2145-8. Danish. PubMed PMID: 18565299.

45: Lo Nigro C, Maffi M, Fischel JL, Formento P, Milano G, Merlano M. The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. BJU Int. 2008 Aug 5;102(5):622-7. Epub 2008 May 20. PubMed PMID: 18494832.

46: Krysiak R, Okopień B, Herman ZS. [Somatostatin analogs]. Pol Arch Med Wewn. 2006 Oct;116(4):988-97. Review. Polish. PubMed PMID: 18416302.

47: Nasir A, Gardner NM, Strosberg J, Ahmad N, Choi J, Malafa MP, Coppola D, Kwekkeboom DJ, Teunissen JJ, Kvols LK. Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels. Pancreas. 2008 Apr;36(3):309-13. PubMed PMID: 18362846.

48: Debono M, Hon LQ, Bax N, Blakeborough A, Newell-Price J. Gluteal nodules in patients with metastatic midgut carcinoid disease treated with depot somatostatin analogs. J Clin Endocrinol Metab. 2008 May;93(5):1860-4. Epub 2008 Feb 26. PubMed PMID: 18303072.

49: Schmitt J, Boullu-Sanchis S, Moreau F, Drui S, Louis B, Chabrier G, Pinget M, Jeandidier N. Association of malignant insulinoma and type 2 diabetes mellitus: a case report. Ann Endocrinol (Paris). 2008 Feb;69(1):69-72. Epub 2008 Mar 4. PubMed PMID: 18291348.

50: Samonakis DN, Notas G, Christodoulakis N, Kouroumalis EA. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci. 2008 Sep;53(9):2359-65. Epub 2008 Feb 14. Review. PubMed PMID: 18273705.

51: Melen-Mucha G, Lawnicka H, Kierszniewska-Stepien D, Komorowski J, Stepien H. The place of somatostatin analogs in the diagnosis and treatment of the neuoroendocrine glands tumors. Recent Pat Anticancer Drug Discov. 2006 Jun;1(2):237-54. Review. PubMed PMID: 18221040.

52: Ben-Shlomo A, Melmed S. Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol. 2008 May 14;286(1-2):192-8. Epub 2007 Nov 29. Review. PubMed PMID: 18191325; PubMed Central PMCID: PMC2697610.

53: Ertorer ME, Bakiner O, Anaforoglu I, Bozkirli E, Tutuncu NB, Demirag NG. Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review. Neuro Endocrinol Lett. 2007 Dec;28(6):727-33. Review. PubMed PMID: 18063933.

54: Ben-Shlomo A, Melmed S. Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs. 2007 Dec;10(12):885-95. PubMed PMID: 18041687.

55: Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, Rowlers S, Trainer PJ, Wass JA. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf). 2008 Jun;68(6):970-5. Epub 2007 Nov 19. PubMed PMID: 18031313.

56: Kinová S, Duris I, Kratochvíl'ová E, Kovácová E, Koren M. Tailored intermittent therapy of carcinoid. Hepatogastroenterology. 2007 Sep;54(78):1716-9. PubMed PMID: 18019702.

57: Fernandez A, Karavitaki N, Ansorge O, Fazal-Sanderson V, Wass JA. Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation? Pituitary. 2008;11(3):325-30. PubMed PMID: 18000757.

58: Auernhammer CJ, Göke B. Medical treatment of gastrinomas. Wien Klin Wochenschr. 2007;119(19-20):609-15. Review. PubMed PMID: 17985097.

59: Kozic D, Medic-Stojanoska M, Ostojic J, Popovic L, Vuckovic N. Application of MR spectroscopy and treatment approaches in a patient with extrapituitary growth hormone secreting macroadenoma. Neuro Endocrinol Lett. 2007 Oct;28(5):560-4. PubMed PMID: 17984954.

60: Hung JS, Chang MC, Lee PH, Tien YW. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? World J Surg. 2007 Dec;31(12):2392-7. PubMed PMID: 17960455.

61: Borbath I, Leclercq IA, Abarca-Quinones J, Desaeger C, Lebrun V, Moulin P, Sempoux C, Horsmans Y. Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide. Cancer Sci. 2007 Dec;98(12):1831-9. Epub 2007 Sep 27. PubMed PMID: 17900309.

62: Zedenius J. Novel therapeutic strategies for neuroendocrine tumours--can eminence replace evidence? Acta Oncol. 2008;47(1):3-4. PubMed PMID: 17891671.

63: Bauzá A, Del Pozo LJ, Escalas J, Mestre F. Radiation recall dermatitis in a patient affected with pheochromocytoma after treatment with lanreotide. Br J Dermatol. 2007 Nov;157(5):1061-3. Epub 2007 Sep 13. PubMed PMID: 17854356.

64: Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A, Caron P. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf). 2007 Aug;67(2):282-9. Epub 2007 May 24. PubMed PMID: 17524029; PubMed Central PMCID: PMC1974833.

65: Correale P, Sciandivasci A, Intrivici C, Pascucci A, Del Vecchio MT, Marsili S, Savelli V, Voltolini L, Di Bisceglie M, Guarnieri A, Gotti G, Francini G. Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation. Br J Cancer. 2007 May 7;96(9):1343-7. Epub 2007 Apr 17. PubMed PMID: 17437022; PubMed Central PMCID: PMC2360193.

66: Colao A, Pivonello R, Di Somma C, Tauchmanovà L, Savastano S, Lombardi G. Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome. Clin Endocrinol (Oxf). 2007 May;66(5):714-22. Epub 2007 Mar 27. PubMed PMID: 17388794.

67: Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Gentilucci A, Lisi D, Passariello R, Gentile V, Di Silverio F. Complete response to the combination therapy with androgen blockade and somatostatin analogue in a patient with advanced prostate cancer: magnetic resonance imaging with 1H-spectroscopy. Eur Urol. 2008 Mar;53(3):652-5. Epub 2007 Feb 15. PubMed PMID: 17316966.

68: Strosberg JR, Kvols LK. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs. 2007 Feb;16(2):219-24. Review. PubMed PMID: 17243941.

69: Bolanowski M, Zatonska K, Kaluzny M, Zielinski G, Bednarek-Tupikowska G, Bohdanowicz-Pawlak A, Daroszewski J, Szymczak J, Podgorski JK. A follow-up of 130 patients with acromegaly in a single centre. Neuro Endocrinol Lett. 2006 Dec;27(6):828-32. PubMed PMID: 17187024.

70: Casarini AP, Pinto EM, Jallad RS, Giorgi RR, Giannella-Neto D, Bronstein MD. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest. 2006 Oct;29(9):826-30. PubMed PMID: 17114915.

71: Battaglia M, Ditonno P, Palazzo S, Bettocchi C, Garofalo L, Selvaggi FP. Lethal somatostatin analog-induced acute necrotizing pancreatitis in a patient with hormone-refractory prostate cancer. Scand J Urol Nephrol. 2006;40(5):423-5. PubMed PMID: 17060090.

72: Bajetta E, Procopio G, Catena L, Martinetti A, De Dosso S, Ricci S, Lecchi AS, Boscani PF, Iacobelli S, Carteni G, De Braud F, Loli P, Tartaglia A, Bajetta R, Ferrari L. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer. 2006 Nov 15;107(10):2474-81. PubMed PMID: 17054107.

73: Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology. 2006;83(3-4):249-57. Epub 2006 Oct 13. Review. PubMed PMID: 17047390.

74: Schäffler A. [Treatment of pituitary gland hyperfunction: from acromegaly to prolactinoma]. Internist (Berl). 2006 Dec;47(12):1215-6, 1218-20, 1222. Review. German. PubMed PMID: 17033781.

75: Beck-Peccoz P, Persani L. TSH-induced hyperthyroidism caused by a pituitary tumor. Nat Clin Pract Endocrinol Metab. 2006 Sep;2(9):524-8; quiz following p528. PubMed PMID: 16957766.

76: Su DH, Liao KM, Chen HW, Chang TC. Long-term primary medical therapy with somatostatin analogs in acromegaly. J Formos Med Assoc. 2006 Aug;105(8):664-9. PubMed PMID: 16935768.

77: Kvols LK, Woltering EA. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs. 2006 Jul;17(6):601-8. Review. PubMed PMID: 16917205.

78: Bronstein MD. Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front Horm Res. 2006;35:129-34. Review. PubMed PMID: 16809928.

79: Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006 Dec;17(12):1733-42. Epub 2006 Jun 26. Review. PubMed PMID: 16801334.

80: Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach. Expert Opin Investig Drugs. 2006 Jul;15(7):795-804. Review. PubMed PMID: 16787142.

81: Burt MG, Ho KK. Newer options in the management of acromegaly. Intern Med J. 2006 Jul;36(7):437-44. Review. PubMed PMID: 16780450.

82: Simonenko VB, Dulin PA, Makanin MA. [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors]. Klin Med (Mosk). 2006;84(4):4-8. Review. Russian. PubMed PMID: 16755846.

83: Livadas S, Hadjidakis DJ, Argyropoulou MI, Stamatelatou M, Kelekis D, Raptis SA. Disappearance of a growth hormone secreting macro adenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal. Hormones (Athens). 2006 Jan-Mar;5(1):57-63. PubMed PMID: 16728386.

84: Petersenn S. Efficacy and limits of somatostatin analogs. J Endocrinol Invest. 2005;28(11 Suppl International):53-7. Review. PubMed PMID: 16625846.

85: Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J Endocrinol Invest. 2005;28(11 Suppl International):36-42. Review. PubMed PMID: 16625843.

86: Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Culler MD. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest. 2005;28(11 Suppl International):21-7. PubMed PMID: 16625841.

87: Sciarra A, Cardi A, Dattilo C, Mariotti G, Di Monaco F, Di Silverio F. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma. Int J Clin Pract. 2006 Apr;60(4):462-70. Review. PubMed PMID: 16620361.

88: Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A, Vignali C, Margutti A, Bondanelli M, Pansini GC, Pelizzo MR, Culler MD, Degli Uberti EC. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. J Clin Endocrinol Metab. 2006 Jun;91(6):2218-24. Epub 2006 Mar 28. PubMed PMID: 16569735.

89: Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A. Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest. 2006 Jan;29(1):86-93. Review. PubMed PMID: 16553040.

90: Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab. 2006 Jun;91(6):2112-8. Epub 2006 Mar 14. PubMed PMID: 16537687.

91: Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol. 2006 Mar;154(3):467-77. PubMed PMID: 16498061.

92: Rodrigues M, Traub-Weidinger T, Li S, Ibi B, Virgolini I. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2006 May;33(5):532-40. Epub 2006 Feb 21. PubMed PMID: 16491425.

93: Molina-Trinidad EM, de Murphy CA, Ferro-Flores G, Murphy-Stack E, Jung-Cook H. Radiopharmacokinetic and dosimetric parameters of 188Re-lanreotide in athymic mice with induced human cancer tumors. Int J Pharm. 2006 Mar 9;310(1-2):125-30. Epub 2006 Jan 19. PubMed PMID: 16423478.

94: Lal A, Chen H. Treatment of advanced carcinoid tumors. Curr Opin Oncol. 2006 Jan;18(1):9-15. Review. PubMed PMID: 16357558.

95: Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer. 2005 Dec;12(4):683-99. Review. PubMed PMID: 16322317.

96: Valencak J, Heere-Ress E, Traub-Weidinger T, Raderer M, Schneeberger A, Thalhammer T, Aust S, Hamilton G, Virgolini I, Pehamberger H. Somatostatin receptor scintigraphy with 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in-vitro and in-vivo results. Melanoma Res. 2005 Dec;15(6):523-9. PubMed PMID: 16314738.

97: Tichomirowa MA, Daly AF, Beckers A. Treatment of pituitary tumors: somatostatin. Endocrine. 2005 Oct;28(1):93-100. Review. PubMed PMID: 16311415.

98: Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2006 Jan;91(1):85-92. Epub 2005 Nov 1. PubMed PMID: 16263832.

99: Biermasz NR, Romijn JA, Pereira AM, Roelfsema F. Current pharmacotherapy for acromegaly: a review. Expert Opin Pharmacother. 2005 Nov;6(14):2393-405. Review. PubMed PMID: 16259571.

100: McStay MK, Maudgil D, Williams M, Tibballs JM, Watkinson AF, Caplin ME, Buscombe JR. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology. 2005 Nov;237(2):718-26. Epub 2005 Sep 28. PubMed PMID: 16192318.

101: Shah T, Caplin M. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):617-36. Review. PubMed PMID: 16183531.

102: Colao A, Pivonello R, Cappabianca P, Briganti F, Tortora F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clin Endocrinol (Oxf). 2005 Sep;63(3):342-9. PubMed PMID: 16117824.

103: Jaquet P, Saveanu A, Barlier A. New SRIF analogs in the control of human pituitary adenomas: perspectives. J Endocrinol Invest. 2005;28(5 Suppl):14-8. Review. PubMed PMID: 16114269.

104: Moody TW, Fuselier J, Coy DH, Mantey S, Pradhan T, Nakagawa T, Jensen RT. Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells. Peptides. 2005 Sep;26(9):1560-6. Epub 2005 Apr 9. PubMed PMID: 16112393.

105: Tartaglia A, Vezzadini C, Bianchini S, Vezzadini P. Gastrinoma of the stomach: a case report. Int J Gastrointest Cancer. 2005;35(3):211-6. PubMed PMID: 16110123.

106: Ferone D, Arvigo M, Semino C, Jaquet P, Saveanu A, Taylor JE, Moreau JP, Culler MD, Albertelli M, Minuto F, Barreca A. Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. Am J Physiol Endocrinol Metab. 2005 Dec;289(6):E1044-50. Epub 2005 Jul 26. PubMed PMID: 16046458.

107: Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol. 2005 Jul;153(1):135-41. PubMed PMID: 15994755.

108: Weiner RE, Thakur ML. Radiolabeled peptides in oncology: role in diagnosis and treatment. BioDrugs. 2005;19(3):145-63. Review. PubMed PMID: 15984900.

109: Novotny J, Janku F, Mares P, Petruzelka L. Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma. Support Care Cancer. 2005 Sep;13(9):760-2. Epub 2005 Jun 16. PubMed PMID: 15959811.

110: Di Girolamo S, Ottaviani F, Floris R, Bruno E, Napolitano B, Schillaci O. Indium111 pentetreotide single photon emission computed tomography (In111 pentetreotide SPECT): a new technique to evaluate somatostatin receptors in chordomas. J Laryngol Otol. 2005 May;119(5):405-8. PubMed PMID: 15949110.

111: Pivonello R, Ferone D, Lamberts SW, Colao A. Cabergoline plus lanreotide for ectopic Cushing's syndrome. N Engl J Med. 2005 Jun 9;352(23):2457-8. PubMed PMID: 15944436.

112: Banerjee S, Das T, Chakraborty S, Samuel G, Korde A, Venkatesh M, Pillai MR. An estradiol-conjugate for radiolabelling with 177Lu: an attempt to prepare a radiotherapeutic agent. Bioorg Med Chem. 2005 Jul 1;13(13):4315-22. PubMed PMID: 15927837.

113: Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P, Dudczak R, Virgolini I. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1144-51. Epub 2005 May 21. PubMed PMID: 15909194.

114: van der Hoek J, Hofland LJ, Lamberts SW. Novel subtype specific and universal somatostatin analogues: clinical potential and pitfalls. Curr Pharm Des. 2005;11(12):1573-92. Review. PubMed PMID: 15892663.

115: Levy MJ, Matharu MS, Meeran K, Powell M, Goadsby PJ. The clinical characteristics of headache in patients with pituitary tumours. Brain. 2005 Aug;128(Pt 8):1921-30. Epub 2005 May 11. PubMed PMID: 15888539.

116: Isidro ML, Iglesias Díaz P, Matías-Guiu X, Cordido F. Acromegaly due to a growth hormone-releasing hormone-secreting intracranial gangliocytoma. J Endocrinol Invest. 2005 Feb;28(2):162-5. PubMed PMID: 15887863.

117: Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 2005 Jul;90(7):4405-10. Epub 2005 Apr 12. PubMed PMID: 15827109.

118: Bondanelli M, Ambrosio MR, Zatelli MC, Cavazzini L, Al Jandali Rifa'y L, degli Uberti EC. Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy. World J Gastroenterol. 2005 Apr 7;11(13):2041-4. PubMed PMID: 15801004.

119: Popadic S, Al-Nahhas A, Naili Q, Todd J, Meeran K. Changes in the expression of somatostatin receptor imaging following Y-90 lanreotide therapy for carcinoid tumor: a flare response? Clin Nucl Med. 2005 Apr;30(4):238-40. PubMed PMID: 15764878.

120: Pegvisomant: new preparation. A last resort in acromegaly. Prescrire Int. 2005 Feb;14(75):10-3. PubMed PMID: 15751152.

121: Boix E, López P, Pérez-Mateo M, Picó A. Lanreotide autogel is a therapeutic option for patients who develop acute pancreatitis after somatostatin analog treatment. J Endocrinol Invest. 2004 Jun;27(6):613-4. PubMed PMID: 15717663.

122: Zatelli MC, Maffei P, Piccin D, Martini C, Rea F, Rubello D, Margutti A, Culler MD, Sicolo N, degli Uberti EC. Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. J Clin Endocrinol Metab. 2005 Apr;90(4):2104-9. Epub 2005 Jan 25. PubMed PMID: 15671091.

123: Ruszniewski P, Ish-Shalom S, Wymenga M, O'Toole D, Arnold R, Tomassetti P, Bax N, Caplin M, Eriksson B, Glaser B, Ducreux M, Lombard-Bohas C, de Herder WW, Delle Fave G, Reed N, Seitz JF, Van Cutsem E, Grossman A, Rougier P, Schmidt W, Wiedenmann B. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology. 2004;80(4):244-51. Epub 2004 Dec 22. PubMed PMID: 15627802.

124: Cerulli C, Sciarra A, Salvatori G, Di Silverio F. Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer. Urology. 2004 Dec;64(6):1231.e1-3. PubMed PMID: 15596212.

125: Kreutzer J, Fahlbusch R. Diagnosis and treatment of pituitary tumors. Curr Opin Neurol. 2004 Dec;17(6):693-703. Review. PubMed PMID: 15542978.

126: Sciarra A, Bosman C, Monti G, Gentile V, Gomez AM, Ciccariello M, Pastore A, Salvatori G, Fattore F, Di Silverio F. Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma. J Urol. 2004 Nov;172(5 Pt 1):1775-83. Review. PubMed PMID: 15540720.

127: Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology. 2004;80 Suppl 1:47-50. PubMed PMID: 15477717.

128: Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abs R, Maiter D. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol. 2004 Sep;151(3):317-24. PubMed PMID: 15362960.

129: Grimberg A. Somatostatin and cancer: applying endocrinology to oncology. Cancer Biol Ther. 2004 Aug;3(8):731-3. Epub 2004 Aug 23. PubMed PMID: 15326367.

130: Hofland LJ, Lamberts SW. Somatostatin receptors in pituitary function, diagnosis and therapy. Front Horm Res. 2004;32:235-52. Review. PubMed PMID: 15281350.

131: Melen-Mucha G, Balcerczak E, Mucha S, Panczyk M, Lipa S, Mirowski M. Expression of p65 gene in experimental colon cancer under the influence of 5-fluorouracil given alone and in combination with hormonal modulation. Neoplasma. 2004;51(4):319-24. PubMed PMID: 15254665.

132: Banerjee S, Das T, Chakraborty S, Samuel G, Korde A, Srivastava S, Venkatesh M, Pillai MR. 177Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy. Nucl Med Biol. 2004 Aug;31(6):753-9. PubMed PMID: 15246366.

133: Lupoli GA, Fonderico F, Fittipaldi MR, Colarusso S, Panico A, Cavallo A, Di Micco L, Lupoli G. The role of somatostatin analogs in the management of medullary thyroid carcinoma. J Endocrinol Invest. 2003;26(8 Suppl):72-4. Review. PubMed PMID: 15233217.

134: Pantanetti P, Sonino N, Arnaldi G, Boscaro M. The quality of life in acromegaly. J Endocrinol Invest. 2003;26(8 Suppl):35-8. PubMed PMID: 15233210.

135: Saveanu A, Gunz G, Dufour H, Enjalbert A, Culler MD, Jaquet P. Distribution and functionality of the somatostatin receptor subtypes in acromegaly. J Endocrinol Invest. 2003;26(8 Suppl):4-7. Review. PubMed PMID: 15233203.

136: Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004 Jun;15(6):966-73. Review. PubMed PMID: 15151956.

137: Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del Basso De Caro ML, Taylor JE, Culler MD, Lombardi G, Di Renzo GF, Annunziato L. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology. 2004 Mar;79(3):142-8. Epub 2004 Apr 16. PubMed PMID: 15103227.

138: Gibril F, Jensen RT. Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours. Dig Liver Dis. 2004 Feb;36 Suppl 1:S106-20. Review. PubMed PMID: 15077919.

139: Kinová S, Kovácová E, Bulas J, Murín J, Belovicová M, Jurkovicová I, Duris I. [Occurrence of carcinoid syndrome in patients with carcinoid tumors]. Vnitr Lek. 2004 Feb;50(2):126-33. Slovak. PubMed PMID: 15077587.

140: Castellani MR, Alessi A, Savelli G, Bombardieri E. The role of radionuclide therapy in medullary thyroid cancer. Tumori. 2003 Sep-Oct;89(5):560-2. Review. PubMed PMID: 14870787.

141: Rubello D, Rufini V, De Carlo E, Martini C, Calcagni ML, Sicolo N, Troncone L, Casara D. [New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues]. Minerva Endocrinol. 2003 Dec;28(4):259-96. Review. Italian. PubMed PMID: 14752399.

142: Völter V, Peschel C. Is lanreotide and/or interferon alfa an adequate therapy for neuroendocrine tumors? J Clin Oncol. 2004 Feb 1;22(3):573; author reply 574-5. PubMed PMID: 14752089.

143: Fazio N, Oberg K. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors. J Clin Oncol. 2004 Feb 1;22(3):573-4; author reply 574-5. PubMed PMID: 14752088.

144: Dimopoulos MA, Kiamouris C, Gika D, Deliveliotis C, Giannopoulos A, Zervas A, Alamanis C, Constantinidis C, Koutsilieris M. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. Urology. 2004 Jan;63(1):120-5. PubMed PMID: 14751362.

145: Lewington VJ. Targeted radionuclide therapy for neuroendocrine tumours. Endocr Relat Cancer. 2003 Dec;10(4):497-501. Review. PubMed PMID: 14713264.

146: de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2003 Dec;10(4):451-8. Review. PubMed PMID: 14713257.

147: Wasko R, Jankowska A, Kotwicka M, Liebert W, Sowinski J, Warchol JB. Effects of treatment with somatostatin analogues on the occurrence of apoptosis in somatotropinomas. Neuro Endocrinol Lett. 2003 Oct;24(5):334-8. PubMed PMID: 14647007.

148: Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, Giusti M, Tamburrano G, Colao A, Cozzi R. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab. 2003 Nov;88(11):5258-65. PubMed PMID: 14602759.

149: Gotthardt M, Béhé MP, Alfke H, Behr TM. Imaging lung tumors with peptide-based radioligands. Clin Lung Cancer. 2003 Sep;5(2):119-24. Review. PubMed PMID: 14596695.

150: De Leo V, La Marca A, Vegni V, Raggi CC, Maggi M, Petraglia F. Quantitative determination of sst2 and sst5 gene expression in uterine leiomyomata and the effect of treatment with somatostatin analogue. Fertil Steril. 2003 Oct;80(4):1058-9. PubMed PMID: 14556835.

151: Di Silverio F, Sciarra A. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer. J Urol. 2003 Nov;170(5):1812-6. PubMed PMID: 14532782.

152: Boehm BO. The therapeutic potential of somatostatin receptor ligands in the treatment of obesity and diabetes. Expert Opin Investig Drugs. 2003 Sep;12(9):1501-9. Review. PubMed PMID: 12943494.

153: Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1338-47. Epub 2003 Aug 21. PubMed PMID: 12937948.

154: Zatelli MC, Piccin D, Bondanelli M, Tagliati F, De Carlo E, Culler MD, Uberti EC. An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro. Horm Metab Res. 2003 Jun;35(6):349-54. PubMed PMID: 12920656.

155: Levy MJ, Bejon P, Barakat M, Goadsby PJ, Meeran K. Acromegaly: a unique human headache model. Headache. 2003 Jul-Aug;43(7):794-7. PubMed PMID: 12890136.

156: Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B; International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003 Jul 15;21(14):2689-96. PubMed PMID: 12860945.

157: Slim K, Le Borgne J. [Drug therapy prevention of pancreatic fistula after pancreaticoduodenectomy]. Ann Chir. 2003 Apr;128(3):175-6. French. PubMed PMID: 12821085.

158: Melmed S, Vance ML, Barkan AL, Bengtsson BA, Kleinberg D, Klibanski A, Trainer PJ. Current status and future opportunities for controlling acromegaly. Pituitary. 2002;5(3):185-96. Review. PubMed PMID: 12812311.

159: Florio T, Thellung S, Corsaro A, Bocca L, Arena S, Pattarozzi A, Villa V, Massa A, Diana F, Schettini D, Barbieri F, Ravetti JL, Spaziante R, Giusti M, Schettini G. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf). 2003 Jul;59(1):115-28. PubMed PMID: 12807513.

160: Li S, Kurtaran A, Li M, Traub-Weidinger T, Kienast O, Schima W, Angelberger P, Virgolini I, Raderer M, Dudczak R. 111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study. Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1087-95. Epub 2003 May 24. PubMed PMID: 12768334.

161: Beckers A, Betea D, Valdes Socin H, Stevenaert A. The treatment of sporadic versus MEN1-related pituitary adenomas. J Intern Med. 2003 Jun;253(6):599-605. PubMed PMID: 12755955.

162: Pawlikowski M, Melen-Mucha G. Perspectives of new potential therapeutic applications of somatostatin analogs. Neuro Endocrinol Lett. 2003 Feb-Apr;24(1-2):21-7. Review. PubMed PMID: 12743527.

163: Colao A, Filippella M, Di Somma C, Manzi S, Rota F, Pivonello R, Gaccione M, De Rosa M, Lombardi G. Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas. Endocrine. 2003 Apr;20(3):279-83. Review. PubMed PMID: 12721508.

164: Tucci A, Bonadonna S, Cattaneo C, Ungari M, Giustina A, Guiseppe R. Transformation of a MGUS to overt multiple myeloma: the possible role of a pituitary macroadenoma secreting high levels of insulin-like growth factor 1 (IGF-1). Leuk Lymphoma. 2003 Mar;44(3):543-5. PubMed PMID: 12688330.

165: Beck-Peccoz P, Persani L. Medical management of thyrotropin-secreting pituitary adenomas. Pituitary. 2002;5(2):83-8. Review. PubMed PMID: 12675505.

166: Racine MS, Barkan AL. Medical management of growth hormone-secreting pituitary adenomas. Pituitary. 2002;5(2):67-76. Review. PubMed PMID: 12675503.

167: Lucas T, Astorga R, Catalá M; Spanish Multicentre Lanreotide Study Group on Acromegaly. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf). 2003 Apr;58(4):471-81. PubMed PMID: 12641631.

168: Chandraharan E, Arulkumaran S. Pituitary and adrenal disorders complicating pregnancy. Curr Opin Obstet Gynecol. 2003 Apr;15(2):101-6. Review. PubMed PMID: 12634600.

169: Ben-Shlomo A, Melmed S. Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab. 2003 Mar;88(3):963-8. Review. PubMed PMID: 12629068.

170: Losa M, Mortini P, Giovanelli M. [The role of somatostatin analogues in the treatment of hypophyseal adenomas]. Minerva Endocrinol. 2003 Mar;28(1):39-51. Review. Italian. PubMed PMID: 12621362.

171: Buscombe JR, Pigott K. New approaches in targeting intracerebral tumours with 90Y-labelled radiopeptides. Eur J Nucl Med Mol Imaging. 2002 Dec;29(12):1697-8. PubMed PMID: 12599329.

172: Zeng J, Wang B, Ma D, Li F. Glucagonoma syndrome: diagnosis and treatment. J Am Acad Dermatol. 2003 Feb;48(2):297-8. PubMed PMID: 12582409.

173: Garland J, Buscombe JR, Bouvier C, Bouloux P, Chapman MH, Chow AC, Reynolds N, Caplin ME. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther. 2003 Feb;17(3):437-44. PubMed PMID: 12562458.

174: Wasko R, Sawicka J, Stachowiak C, Kozak W, Junik R, Sowinski J. [Effect of lanreotide on prolactin level in patients with pituitary mixed tumors]. Ann Endocrinol (Paris). 2002 Dec;63(6 Pt 1):532-5. French. PubMed PMID: 12527855.

175: Shimon I, Nass D, Gross DJ. Pituitary macroadenoma secreting thyrotropin and growth hormone: remission of bihormonal hypersecretion in response to lanreotide therapy. Pituitary. 2001 Sep;4(4):265-9. PubMed PMID: 12501978.

176: Arnold R, Wied M, Behr TH. Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opin Pharmacother. 2002 Jun;3(6):643-56. Review. Erratum in: Expert Opin Pharmacother. 2002 Jul;3(7):1029. PubMed PMID: 12472080.

177: Weiner RE, Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot. 2002 Nov;57(5):749-63. Review. PubMed PMID: 12433051.

178: Díez JJ, Iglesias P. Somatostatin analogs in the treatment of medullary thyroid carcinoma. J Endocrinol Invest. 2002 Oct;25(9):773-8. PubMed PMID: 12398235.

179: Froidevaux S, Eberle AN. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers. 2002;66(3):161-83. Review. PubMed PMID: 12385036.

180: Elizalde I, Borda F. [Current treatment of carcinoid tumor]. Gastroenterol Hepatol. 2002 Oct;25(8):508-13. Review. Spanish. PubMed PMID: 12361534.

181: Rohaizak M, Farndon JR. Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours. ANZ J Surg. 2002 Sep;72(9):635-8. PubMed PMID: 12269913.

182: Colao A, De Rosa M, Pivonello R, Balestrieri A, Cappabianca P, Di Sarno A, Rochira V, Carani C, Lombardi G. Short-term suppression of GH and IGF-I levels improves gonadal function and sperm parameters in men with acromegaly. J Clin Endocrinol Metab. 2002 Sep;87(9):4193-7. PubMed PMID: 12213870.

183: Ayuk J, Stewart SE, Stewart PM, Sheppard MC. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab. 2002 Sep;87(9):4142-6. PubMed PMID: 12213862.

184: Balsa JA, Varela C, Lucas T, García-Uría J, Barceló B, Sancho-Rof JM. Varying additive effects of bromocriptine with two somatostatin analogs in cultures of GH-secreting adenomas. Horm Metab Res. 2002 Aug;34(8):435-40. PubMed PMID: 12198598.

185: Kinova S, Duris I, Kratochvilova E, Ondrejka P, Payer J. Carcinoid tumors--somatostatine in the diagnosis and therapy. Bratisl Lek Listy. 2002;103(3):108-12. PubMed PMID: 12190042.

186: Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Burggasser G, Andreae F, Kurtaran A, Dudczak R. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des. 2002;8(20):1781-807. Review. PubMed PMID: 12171531.

187: Gourgiotis L, Skarulis MC, Brucker-Davis F, Oldfield EH, Sarlis NJ. Effectiveness of long-acting octreotide in suppressing hormonogenesis and tumor growth in thyrotropin-secreting pituitary adenomas: report of two cases. Pituitary. 2001 Aug;4(3):135-43. PubMed PMID: 12138986.

188: Migliori M, Tomassetti P, Lalli S, Casadei R, Santini D, Corinaldesi R, Gullo L. Carcinoid of the pancreas. Pancreatology. 2002;2(2):163-6. PubMed PMID: 12123097.

189: Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2002 Jul;87(7):3013-8. Review. PubMed PMID: 12107192.

190: Boix E, Picó A, Pinedo R, Aranda I, Kovacs K. Ectopic growth hormone-releasing hormone secretion by thymic carcinoid tumour. Clin Endocrinol (Oxf). 2002 Jul;57(1):131-4. PubMed PMID: 12100081.

191: Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol. 2002 May;13(5):653-68. Review. PubMed PMID: 12075733.

192: Boushey RP, Dackiw AP. Carcinoid tumors. Curr Treat Options Oncol. 2002 Aug;3(4):319-26. Review. PubMed PMID: 12074768.

193: Góth M, Hubina E, Kovács L, Szabolcs I. [Novel pharmacologic therapies in acromegaly]. Orv Hetil. 2002 May 12;143(19 Suppl):1057-62. Review. Hungarian. PubMed PMID: 12063860.

194: Zatelli MC, Tagliati F, Taylor JE, Piccin D, Culler MD, degli Uberti EC. Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. Horm Metab Res. 2002 May;34(5):229-33. PubMed PMID: 12063634.

195: McCormick D. Carcinoid tumors and syndrome. Gastroenterol Nurs. 2002 May-Jun;25(3):105-11. Review. PubMed PMID: 12055378.

196: Kinová S, Kovácová E, Kratochvíĺová E, Ondrejka P, Duris I. [Diurnal rhythm of endogenous somatostatin in patients with carcinoid]. Cesk Fysiol. 2002 May;51(2):69-74. Slovak. PubMed PMID: 12053490.

197: Buscail L, Vernejoul F, Faure P, Torrisani J, Susini C. [Regulation of cell proliferation by somatostatin]. Ann Endocrinol (Paris). 2002 Apr;63(2 Pt 3):2S13-8. Review. French. PubMed PMID: 12037498.

198: Fjällskog ML, Sundin A, Westlin JE, Oberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol. 2002;19(1):35-42. PubMed PMID: 12025889.

199: England RJ, Atkin SL. Somatostatins and their role in thyroid cancer. Clin Otolaryngol Allied Sci. 2002 Apr;27(2):120-3. Review. PubMed PMID: 11994118.

200: Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002 Apr;32(2):148-55. PubMed PMID: 11965610.

201: Warner RR, O'dorisio TM. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. Semin Nucl Med. 2002 Apr;32(2):79-83. Review. PubMed PMID: 11965602.

202: Lightman S. Somatuline Autogel: an extended release lanreotide formulation. Hosp Med. 2002 Mar;63(3):162-5. Review. PubMed PMID: 11933820.

203: Falconi M, Contro C, Ballabio M, Bassi C, Salvia R, Pederzoli P. Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose: preliminary study. Dig Liver Dis. 2002 Feb;34(2):127-32. PubMed PMID: 11926556.

204: Waśko R, Bolko P, Kostrzewski J, Horst-Sikorska W, Liebert W, Sowiński J. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma]. Pol Arch Med Wewn. 2001 Aug;106(2):693-8. Polish. PubMed PMID: 11926144.

205: Palmieri G, Montella L, Martignetti A, Muto P, Di Vizio D, De Chiara A, Lastoria S. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer. 2002 Mar 1;94(5):1414-20. PubMed PMID: 11920496.

206: Basili E, Allemand I, Ville E, Laugier R. [Lanreotide acetate may cure cystic dystrophy in heterotopic pancreas of the duodenal wall]. Gastroenterol Clin Biol. 2001 Dec;25(12):1108-11. French. PubMed PMID: 11910994.

207: Wahid ST, Marbach P, Stolz B, Miller M, James RA, Ball SG. Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues. Eur J Endocrinol. 2002 Mar;146(3):295-302. PubMed PMID: 11888834.

208: Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf). 2002 Jan;56(1):65-71. PubMed PMID: 11849248.

209: Fiebiger WC, Scheithauer W, Traub T, Kurtaran A, Gedlicka C, Kornek GV, Virgolini I, Raderer M. Absence of therapeutic efficacy of the somatostatin analogue lanreotide in advanced primary hepatic cholangiocellular cancer and adenocarcinoma of the gallbladder despite in vivo somatostatin-receptor expression. Scand J Gastroenterol. 2002 Feb;37(2):222-5. PubMed PMID: 11843061.

210: de Herder WW, Lamberts SW. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol. 2002 Jan;14(1):53-7. Review. PubMed PMID: 11790981.

211: Cozzi R, Barausse M, Sberna M, Lodrini A, Franzini A, Lasio G, Attanasio R. Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly. Pituitary. 2000 Dec;3(4):231-8. PubMed PMID: 11788011.

212: Uomo G, Germano D, Rabitti PG. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours]. Minerva Endocrinol. 2001 Dec;26(4):225-9. Review. Italian. PubMed PMID: 11782707.

213: Doga M, Bonadonna S, Burattin A, Giustina A. Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects. Ann Oncol. 2001;12 Suppl 2:S89-94. Review. PubMed PMID: 11762359.

214: Virgolini I, Patri P, Novotny C, Traub T, Leimer M, Füger B, Li SR, Angelberger P, Raderer M, Wogritsch S, Kurtaran A, Kletter K, Dudczak R. Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol. 2001;12 Suppl 2:S41-5. PubMed PMID: 11762351.

215: Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol. 2001;12 Suppl 2:S111-4. Review. PubMed PMID: 11762335.

216: Dogliotti L, Tampellini M, Stivanello M, Gorzegno G, Fabiani L. The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy. Ann Oncol. 2001;12 Suppl 2:S105-9. Review. PubMed PMID: 11762334.

217: Colao A, Dorato M, Pulcrano M, Rossi FW, Auriemma RS, Lombardi G, Lastoria S. [Somatostatin analogs in the clinical management of pituitary neoplasms]. Minerva Endocrinol. 2001 Sep;26(3):181-91. Review. Italian. PubMed PMID: 11753242.

218: Sinisi AA, Bellastella A, Pasquali D. [Somatostatin and somatostatin receptors in the prostate]. Minerva Endocrinol. 2001 Sep;26(3):159-63. Review. Italian. PubMed PMID: 11753239.

219: Panzuto F, Nasoni S, Delle Fave G. [Medical treatment of digestive neuroendocrine tumours]. Minerva Endocrinol. 2001 Sep;26(3):145-8. Review. Italian. PubMed PMID: 11753237.

220: Fueger BJ, Hamilton G, Raderer M, Pangerl T, Traub T, Angelberger P, Baumgartner G, Dudczak R, Virgolini I. Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. J Nucl Med. 2001 Dec;42(12):1856-62. PubMed PMID: 11752085.

221: Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab. 2001 Dec;86(12):5729-36. PubMed PMID: 11739429.

222: Schopohl J, Gutt B. [Therapy of pituitary diseases. What can be achieved with medication and hormones?]. MMW Fortschr Med. 2001 Nov 1;143(44):34-9. Review. German. PubMed PMID: 11732393.

223: Zieliński G, Podgórski JK, Koziarski A, Siwik J, Zgliczyński W, Wieliczko W. [Preoperative administration of a slow releasing somatostatin analog (SR-lanreotide, BIM 23014) in patients with acromegaly in the course of GH-releasing adenoma]. Neurol Neurochir Pol. 2001 Mar-Apr;35(3):423-37. Polish. PubMed PMID: 11732266.

224: Cannavò S, Squadrito S, Curtò L, Almoto B, Trimarchi F. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma. Horm Metab Res. 2001 Oct;33(10):618-24. PubMed PMID: 11607883.

225: Traub T, Petkov V, Ofluoglu S, Pangerl T, Raderer M, Fueger BJ, Schima W, Kurtaran A, Dudczak R, Virgolini I. 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med. 2001 Sep;42(9):1309-15. PubMed PMID: 11535718.

226: Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001 Jul;28(7):836-46. Erratum in: Eur J Nucl Med 2001 Sep;28(9):1433. PubMed PMID: 11504080.

227: Ganim RB, Norton JA. Recent advances in carcinoid pathogenesis, diagnosis and management. Surg Oncol. 2000 Dec;9(4):173-9. Review. PubMed PMID: 11476988.

228: Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Andreae F, Kurtaran A, Dudczak R. New trends in peptide receptor radioligands. Q J Nucl Med. 2001 Jun;45(2):153-9. Review. PubMed PMID: 11476164.

229: Melen-Mucha G, Winczyk K, Pawlikowski M. Effects of somatostatin analogs octreotide and lanreotide on the proliferation and apoptosis in colon 38 tumor: interaction with 5-fluorouracil. Neuro Endocrinol Lett. 2000;21(2):137-142. PubMed PMID: 11455343.

230: Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab. 2001 Jul;86(7):2976-81. PubMed PMID: 11443154.

231: Neal JM. Successful pregnancy in a woman with acromegaly treated with octreotide. Endocr Pract. 2000 Mar-Apr;6(2):148-50. PubMed PMID: 11421531.

232: Saveanu A, Morange-Ramos I, Gunz G, Dufour H, Enjalbert A, Jaquet P. A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies. Eur J Endocrinol. 2001 Jul;145(1):35-41. PubMed PMID: 11415850.

233: Tulipano G, Bonfanti C, Milani G, Billeci B, Bollati A, Cozzi R, Maira G, Murphy WA, Poiesi C, Turazzi S, Giustina A. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology. 2001 May;73(5):344-51. PubMed PMID: 11399907.

234: Attanasio R, Barausse M, Cozzi R. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. J Endocrinol Invest. 2001 Apr;24(4):209-16. PubMed PMID: 11383906.

235: Rufini V, Salvatori M, Garganese MC, Di Giuda D, Lodovica Maussier M, Troncone L. Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays. 2000 Apr-Jun;25(2):273-82. Review. English, Italian. PubMed PMID: 11370545.

236: Berruti A, Dogliotti L, Mosca A, Tarabuzzi R, Torta M, Mari M, Gorzegno G, Fontana D, Angeli A. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients. Prostate. 2001 May 15;47(3):205-11. PubMed PMID: 11351350.

237: Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, degli Uberti EC. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J Clin Endocrinol Metab. 2001 May;86(5):2161-9. PubMed PMID: 11344221.

238: Bomanji JB, Hyder SW, Gaze MN, Gacinovic S, Costa DC, Coulter C, Ell PJ. Functional imaging as an aid to decision-making in metastatic paraganglioma. Br J Radiol. 2001 Mar;74(879):266-9. PubMed PMID: 11338105.

239: Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E, Schlumberger M, Rougier P. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer. 2001 May;37(8):1014-9. PubMed PMID: 11334727.

240: Arteaga de Murphy C, Pedraza-López M, Ferro-Flores G, Murphy-Stack E, Chávez-Mercado L, Ascencio JA, García-Salinas L, Hernández-Gutiérrez S. Uptake of (188)Re-beta-naphthyl-peptide in cervical carcinoma tumours in athymic mice. Nucl Med Biol. 2001 Apr;28(3):319-26. PubMed PMID: 11323244.

241: Dolan JT, Miltenburg DM, Granchi TS, Miller CC 3rd, Brunicardi FC. Treatment of metastatic breast cancer with somatostatin analogues--a meta-analysis. Ann Surg Oncol. 2001 Apr;8(3):227-33. PubMed PMID: 11314939.

242: Luna V, Morales F, Luengo LM, Sanz A, Diaz J. Pituitary gangliocytoma-adenoma presenting with acromegaly: response to treatment. Arch Intern Med. 2001 Apr 9;161(7):1010-1. PubMed PMID: 11295968.

243: Jenkins SA, Kynaston HG, Davies ND, Baxter JN, Nott DM. Somatostatin analogs in oncology: a look to the future. Chemotherapy. 2001;47 Suppl 2:162-96. Review. PubMed PMID: 11275709.

244: Oberg K. Established clinical use of octreotide and lanreotide in oncology. Chemotherapy. 2001;47 Suppl 2:40-53. Review. PubMed PMID: 11275701.

245: Scarpignato C, Pelosini I. Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy. 2001;47 Suppl 2:1-29. Review. PubMed PMID: 11275699.

246: Díez JJ, Iglesias P. Current management of acromegaly. Expert Opin Pharmacother. 2000 Jul;1(5):991-1006. Review. PubMed PMID: 11249504.

247: Raderer M, Kurtaran A, Scheithauer W, Fiebiger W, Weinlaender G, Oberhuber G. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. Oncology. 2001;60(2):141-5. PubMed PMID: 11244329.

248: De Leo V, la Marca A, Morgante G, Severi FM, Petraglia F. Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata. Fertil Steril. 2001 Mar;75(3):632-3. PubMed PMID: 11239556.

249: Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab. 2001 Jan;86(1):140-5. PubMed PMID: 11231991.

250: Pichler R, Maschek W. Long-term treatment of thyrotropin-secreting microadenoma with lanreotide and cabergoline. Eur J Endocrinol. 2001 Feb;144(2):179-80. PubMed PMID: 11182755.

251: Todd JF, Meeran K. The tumour vanishes. Clin Endocrinol (Oxf). 2000 Dec;53(6):663-4. PubMed PMID: 11155085.

252: Tesei A, Ricotti L, De Paola F, Casini-Raggi C, Barzanti F, Frassineti GL, Zoli W. Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines: a preclinical study. J Chemother. 2000 Oct;12(5):421-30. PubMed PMID: 11128563.

253: Ilias I, Mastorakos G. [Complete regression of a somatotropin-secreting adenoma with lanreotide monotherapy]. Presse Med. 2000 Nov 4;29(33):1818-9. French. PubMed PMID: 11109436.

254: Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R, Genestin E, Hammel P, Rougier P. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000 Nov;95(11):3276-81. PubMed PMID: 11095353.

255: Zalatnai A, Pogány V. [Somatostatin analogs in the treatment of pancreatic cancer: utopia or feasible alternative?]. Orv Hetil. 2000 Oct 22;141(43):2333-8. Review. Hungarian. PubMed PMID: 11089387.

256: Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J, Pagani G. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol. 2000 Nov;143(5):577-84. PubMed PMID: 11078980.

257: Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol. 2000 Sep;11(9):1127-30. PubMed PMID: 11061606.

258: Kaal A, Orskov H, Nielsen S, Pedroncelli AM, Lancranjan I, Marbach P, Weeke J. Occurrence and effects of octreotide antibodies during nasal, subcutaneous and slow release intramuscular treatment. Eur J Endocrinol. 2000 Sep;143(3):353-61. PubMed PMID: 11022177.

259: Giusti M, Bocca L, Florio T, Foppiani L, Corsaro A, Auriati L, Spaziante R, Schettini G, Giordano G. Cabergoline modulation of alpha-subunits and FSH secretion in a gonadotroph adenoma. J Endocrinol Invest. 2000 Jul-Aug;23(7):463-6. PubMed PMID: 11005271.

260: Capron F, Fialip S, Guitard I, Lasser P, Billard V. [Perianesthetic management of carcinoid syndrome: contribution of the bispectral EEG index]. Ann Fr Anesth Reanim. 2000 Aug;19(7):552-5. French. PubMed PMID: 10976372.

261: Colao A, Di Sarno A, Marzullo P, Di Somma C, Cerbone G, Landi ML, Faggiano A, Merola B, Lombardi G. New medical approaches in pituitary adenomas. Horm Res. 2000;53 Suppl 3:76-87. Review. PubMed PMID: 10971110.

262: Froidevaux S, Heppeler A, Eberle AN, Meier AM, Häusler M, Beglinger C, Béhé M, Powell P, Mäcke HR. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology. 2000 Sep;141(9):3304-12. PubMed PMID: 10965902.

263: Ricci S, Antonuzzo A, Galli L, Orlandini C, Ferdeghini M, Boni G, Roncella M, Mosca F, Conte PF. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol. 2000 Aug;23(4):412-5. PubMed PMID: 10955874.

264: Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med. 2000 Aug 24;343(8):551-4. PubMed PMID: 10954763.

265: Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion. 2000;62 Suppl 1:84-91. Review. PubMed PMID: 10940693.

266: Bajetta E, Bichisao E, Artale S, Celio L, Ferrari L, Di Bartolomeo M, Zilembo N, Stani SC, Buzzoni R. New clinical trials for the treatment of neuroendocrine tumors. Q J Nucl Med. 2000 Mar;44(1):96-101. Review. PubMed PMID: 10932606.

267: Virgolini I, Traub T, Leimer M, Novotny C, Pangerl T, Ofluoglu S, Halvadjieva E, Smith-Jones P, Flores J, Li SR, Angelberger P, Havlik E, Andreae F, Raderer M, Kurtaran A, Niederle B, Dudczak R. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q J Nucl Med. 2000 Mar;44(1):50-8. Review. PubMed PMID: 10932601.

268: Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem. 2000 Sep;7(9):971-94. Review. PubMed PMID: 10911025.

269: Stewart PM, James RA. The future of somatostatin analogue therapy. Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Oct;13(3):409-18. Review. PubMed PMID: 10909432.

270: Ozker K. Current developments in single photon radiopharmaceuticals for tumor imaging. Curr Pharm Des. 2000 Jul;6(11):1123-6. Review. PubMed PMID: 10903385.

271: Cannavò S, Squadrito S, Curtò L, Almoto B, Vieni A, Trimarchi F. Results of a two-year treatment with slow release lanreotide in acromegaly. Horm Metab Res. 2000 Jun;32(6):224-9. PubMed PMID: 10898551.

272: Raderer M, Hejna MH, Muller C, Kornek GV, Kurtaran A, Virgolini I, Fiebieger W, Hamilton G, Scheithauer W. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol. 2000 Jun;16(6):1197-201. PubMed PMID: 10811995.

273: Tomassetti P, Migliori M, Corinaldesi R, Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther. 2000 May;14(5):557-60. PubMed PMID: 10792118.

274: Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000 Mar;27(3):273-82. PubMed PMID: 10774879.

275: Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, Chanson P, Tabarin A, Goth MI, Blumberg J, Catus F, Ispas S, Beck-Peccoz P. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab. 2000 Apr;85(4):1487-91. PubMed PMID: 10770186.

276: Murillo Sanchís J, Martín AL, Salinas Vert I, Sanmartí Sala A. [Excellent response to lanreotide treatment of thyrotropin and prolactin secreting pituitary macroadenoma]. Med Clin (Barc). 2000 Feb 19;114(6):238. Spanish. PubMed PMID: 10757110.

277: Vitale G, Tagliaferri P, Caraglia M, Rampone E, Ciccarelli A, Bianco AR, Abbruzzese A, Lupoli G. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab. 2000 Mar;85(3):983-8. PubMed PMID: 10720027.

278: Janson ET, Kälkner KM, Eriksson B, Westlin JE, Oberg K. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors. Nucl Med Biol. 1999 Nov;26(8):877-82. PubMed PMID: 10708300.

279: Waśko R, Ruchała M, Sawicka J, Kotwicka M, Liebert W, Sowiński J. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly. J Endocrinol Invest. 2000 Jan;23(1):12-8. PubMed PMID: 10698045.

280: O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouché O, Catus F, Blumberg J, Ruszniewski P. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000 Feb 15;88(4):770-6. PubMed PMID: 10679645.

281: Culler M. Lanreotide and beyond: extending the therapeutic horizons. Hosp Med. 1999 Oct;60(10):714-7. PubMed PMID: 10656063.

282: Pape UF, Höcker M, Seuss U, Wiedenmann B. New molecular aspects in the diagnosis and therapy of neuroendocrine tumors of the gastroenteropancreatic system. Recent Results Cancer Res. 2000;153:45-60. Review. PubMed PMID: 10626288.

283: Fehmann HC, Wulbrand U, Arnold R. Treatment of endocrine gastroenteropancreatic tumors with somatostatin analogues. Recent Results Cancer Res. 2000;153:15-22. Review. PubMed PMID: 10626286.

284: Sadoul JL. [Somatotrope pituitary adenomas. Contribution of presurgical treatment with somatostatin analogs]. Ann Endocrinol (Paris). 1999 Dec;60(6):490-3. Review. French. PubMed PMID: 10617802.

285: Virgolini I, Kurtaran A, Angelberger P, Raderer M, Havlik E, Smith-Jones P. "MAURITIUS": tumour dose in patients with advanced carcinoma. Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S227-30. PubMed PMID: 10604137.

286: Anthony LB. Long-acting formulations of somatostatin analogues. Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S216-8. Review. PubMed PMID: 10604134.

287: Höcker M, Wiedenmann B. Therapeutic and diagnostic implications of the somatostatin system in gastroenteropancreatic neuroendocrine tumour disease. Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S139-42. Review. PubMed PMID: 10604118.

288: Palmieri G, Lastoria S, Montella L, Martignetti A, Lombardi G, Salvatore M, Bianco AR. Role of somatostatin analogue-based therapy in unresponsive malignant thymomas. Ann Med. 1999 Oct;31 Suppl 2:80-5. PubMed PMID: 10574161.

289: Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, Välimäki MJ, Renstrup J, de Vries EG, Oberg KE. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol. 1999 Apr;17(4):1111. PubMed PMID: 10561168.

290: Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, Peck-Radosavljevic M, Hamilton G, Kaserer K, Kofler A, Schlangbauer-Wadl H, Traub T, Virgolini I. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology. 1999 Nov;140(11):5136-48. PubMed PMID: 10537142.

291: Florio T, Thellung S, Arena S, Corsaro A, Spaziante R, Gussoni G, Acuto G, Giusti M, Giordano G, Schettini G. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol. 1999 Oct;141(4):396-408. PubMed PMID: 10526255.

292: Cattaneo MG, Scita G, Vicentini LM. Somatostatin inhibits PDGF-stimulated Ras activation in human neuroblastoma cells. FEBS Lett. 1999 Oct 1;459(1):64-8. PubMed PMID: 10508918.

293: Faiss S, Räth U, Mansmann U, Caird D, Clemens N, Riecken EO, Wiedenmann B. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion. 1999 Sep-Oct;60(5):469-76. PubMed PMID: 10473972.

294: Suliman M, Jenkins R, Ross R, Powell T, Battersby R, Cullen DR. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. J Endocrinol Invest. 1999 Jun;22(6):409-18. PubMed PMID: 10435849.

295: Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol. 1999;10 Suppl 2:S31-8. Review. PubMed PMID: 10399030.

296: Calvo Romero JM, Morales Pérez F, Alvarez Barreiro JA, Díaz Pérez de Madrid J. [Thyrotropin-producing hypophyseal adenomas]. Rev Clin Esp. 1999 May;199(5):285-7. Review. Spanish. PubMed PMID: 10396149.

297: Cuntz MC, Levine EA, O'Dorisio TM, Watson JC, Wray DA, Espenan GD, McKnight C, Meier JR, Weber LJ, Mera R, O'Dorisio MS, Woltering EA. Intraoperative gamma detection of 125I-lanreotide in women with primary breast cancer. Ann Surg Oncol. 1999 Jun;6(4):367-72. PubMed PMID: 10379857.

298: Madeira I, Ruszniewski P. [Digestive system carcinoid tumors: treatment]. Rev Med Interne. 1999 May;20(5):421-6. Review. French. PubMed PMID: 10365413.

299: Krassowski J, Zgliczyński W, Jeske W, Zgliczyński S. Comment of long-acting lanreotide inducing clinical and biochemical remission of acromegaly caused by disseminated GHRH secreting carcinoid. J Clin Endocrinol Metab. 1999 May;84(5):1761-2. PubMed PMID: 10323416.

300: Gaztambide S, Vazquez JA. Short- and long-term effect of a long-acting somatostatin analogue, lanreotide (SR-L) on metastatic gastrinoma. J Endocrinol Invest. 1999 Feb;22(2):144-6. PubMed PMID: 10195383.

301: Koutsilieris M, Tzanela M, Dimopoulos T. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report. Prostate. 1999 Mar 1;38(4):313-6. PubMed PMID: 10075011.

302: Raderer M, Hamilton G, Kurtaran A, Valencak J, Haberl I, Hoffmann O, Kornek GV, Vorbeck F, Hejna MH, Virgolini I, Scheithauer W. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results. Br J Cancer. 1999 Feb;79(3-4):535-7. PubMed PMID: 10027326; PubMed Central PMCID: PMC2362412.

303: Raderer M, Hejna MH, Kurtaran A, Kornek GV, Valencak JB, Oberhuber G, Vorbeck F, Virgolini I, Scheithauer W. Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide. Am J Gastroenterol. 1999 Jan;94(1):278-9. PubMed PMID: 9934776.

304: Chanson P. [Treatment of pituitary adenoma]. Presse Med. 1998 Dec 12;27(39):2077-87. Review. French. PubMed PMID: 9893701.

305: Leimer M, Kurtaran A, Smith-Jones P, Raderer M, Havlik E, Angelberger P, Vorbeck F, Niederle B, Herold C, Virgolini I. Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. J Nucl Med. 1998 Dec;39(12):2090-4. PubMed PMID: 9867148.

306: Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, Vorbeck F, Bischof C, Leimer M, Dorner G, Kletter K, Niederle B, Scheithauer W, Smith-Jones P. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med. 1998 Nov;39(11):1928-36. PubMed PMID: 9829585.

307: Drange MR, Melmed S. Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid. J Clin Endocrinol Metab. 1998 Sep;83(9):3104-9. PubMed PMID: 9745411.

308: Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol. 1998 Sep;93(9):1468-71. PubMed PMID: 9732927.

309: Damgé C, Hajri A. Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma. Eur J Pharmacol. 1998 Apr 17;347(1):77-86. PubMed PMID: 9650851.

310: Jadresic A. [Medical treatment of prolactin and growth hormone-secreting pituitary tumors]. Rev Med Chil. 1997 Nov;125(11):1383-8. Spanish. PubMed PMID: 9609063.

311: Gillespie TJ, Erenberg A, Kim S, Dong J, Taylor JE, Hau V, Davis TP. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther. 1998 Apr;285(1):95-104. PubMed PMID: 9535998.

312: McCarthy KE, Woltering EA, Espenan GD, Cronin M, Maloney TJ, Anthony LB. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions. Cancer J Sci Am. 1998 Mar-Apr;4(2):94-102. PubMed PMID: 9532411.

313: Imam H, Gobl A, Eriksson B, Oberg K. Interferon-alpha induces bcl-2 proto-oncogene in patients with neuroendocrine gut tumor responding to its antitumor action. Anticancer Res. 1997 Nov-Dec;17(6D):4659-65. PubMed PMID: 9494585.

314: Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997 Nov 1;100(9):2386-92. PubMed PMID: 9410919; PubMed Central PMCID: PMC508437.

315: Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol. 1997 Oct;8(10):1041-4. PubMed PMID: 9402179.

316: Shimon I, Melmed S. Structure and function of somatostatin receptors in growth hormone control. J Endocrinol. 1997 Oct;155 Suppl 1:S3-6; discussion S7-8. PubMed PMID: 9389989.

317: Tentler JJ, Hadcock JR, Gutierrez-Hartmann A. Somatostatin acts by inhibiting the cyclic 3',5'-adenosine monophosphate (cAMP)/protein kinase A pathway, cAMP response element-binding protein (CREB) phosphorylation, and CREB transcription potency. Mol Endocrinol. 1997 Jun;11(7):859-66. PubMed PMID: 9178746.

318: Chanson P. Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits? Eur J Endocrinol. 1997 Apr;136(4):359-61. PubMed PMID: 9150692.

319: Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, Oberg K. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol. 1997;36(6):607-14. PubMed PMID: 9408151.

320: Bogden AE, Moreau JP, Eden PA. Proliferative response of human and animal tumours to surgical wounding of normal tissues: onset, duration and inhibition. Br J Cancer. 1997;75(7):1021-7. PubMed PMID: 9083338; PubMed Central PMCID: PMC2222742.

321: Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab. 1997 Jan;82(1):18-22. PubMed PMID: 8989225.

322: Cattaneo MG, Amoroso D, Gussoni G, Sanguini AM, Vicentini LM. A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines. FEBS Lett. 1996 Nov 18;397(2-3):164-8. PubMed PMID: 8955339.

323: Giustina A, Zaltieri G, Negrini F, Wehrenberg WB. The pharmacological aspects of the treatment of acromegaly. Pharmacol Res. 1996 Nov-Dec;34(5-6):247-68. Review. PubMed PMID: 9076850.

324: Ruszniewski P, Ducreux M, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R, Genestin E, Bernades P, Rougier P. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut. 1996 Aug;39(2):279-83. PubMed PMID: 8977344; PubMed Central PMCID: PMC1383312.

325: de Herder WW, van der Lely AJ, Lamberts SW. Somatostatin analogue treatment of neuroendocrine tumours. Postgrad Med J. 1996 Jul;72(849):403-8. Review. PubMed PMID: 8935599; PubMed Central PMCID: PMC2398518.

326: Skinazi F, Zins M, Menu Y, Bernades P, Ruszniewski P. Liver metastases of digestive endocrine tumours: natural history and response to medical treatment. Eur J Gastroenterol Hepatol. 1996 Jul;8(7):673-8. PubMed PMID: 8853257.

327: Di Leo A, Bajetta E, Ferrari L, Biganzoli L, Mariani L, Carnaghi C, Camerini E, Buzzoni R, Ruiz JM. A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma. Cancer. 1996 Jul 1;78(1):35-42. PubMed PMID: 8646723.

328: Chanson P. [Medical treatment of pituitary adenoma]. Rev Prat. 1996 Jun 15;46(12):1509-13. French. PubMed PMID: 8881166.

329: Janson ET, Gobl A, Kälkner KM, Oberg K. A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res. 1996 Jun 1;56(11):2561-5. PubMed PMID: 8653698.

330: Prevost G, Veber N, Viollet C, Roubert V, Roubert P, Benard J, Eden P. Somatostatin-14 mainly binds the somatostatin receptor subtype 2 in human neuroblastoma tumors. Neuroendocrinology. 1996 Feb;63(2):188-97. PubMed PMID: 9053784.

331: Faiss S, Scherübl H, Riecken EO, Wiedenmann B. Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. Recent Results Cancer Res. 1996;142:193-207. Review. PubMed PMID: 8893342.

332: Faiss S, Scherübl H, Riecken EO, Wiedenmann B. Interferon-alpha versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours. Digestion. 1996;57 Suppl 1:84-5. PubMed PMID: 8813478.

333: Eriksson B, Janson ET, Bax ND, Mignon M, Morant R, Opolon P, Rougier P, Oberg KE. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours. Digestion. 1996;57 Suppl 1:77-80. PubMed PMID: 8813476.

334: Bajetta E, Carnaghi C, Ferrari L, Spagnoli I, Mazzaferro V, Buzzoni R. The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumours. Digestion. 1996;57 Suppl 1:72-6. Review. PubMed PMID: 8813475.

335: Albers AR, O'Dorisio MS. Clinical use of somatostatin analogues in paediatric oncology. Digestion. 1996;57 Suppl 1:38-41. Review. PubMed PMID: 8813466.

336: Bogden AE, LePage D, Zwicker S, Grant W, Silver M. Proliferative response of human prostate tumour xenografts to surgical trauma and the transurethral resection of the prostate controversy. Br J Cancer. 1996 Jan;73(1):73-8. PubMed PMID: 8554987; PubMed Central PMCID: PMC2074276.

337: Bergström M, Eriksson B, Oberg K, Sundin A, Ahlström H, Lindner KJ, Bjurling P, Långström B. In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine. J Nucl Med. 1996 Jan;37(1):32-7. PubMed PMID: 8543997.

338: Mannant PR, Beau P, De Lédinghen V, Barrioz T, Genestin E. [Partial regression of a desmoid tumor after prolonged treatment with lanreotide]. Gastroenterol Clin Biol. 1995 Dec;19(12):1072-3. French. PubMed PMID: 8729428.

339: Canobbio L, Cannata D, Miglietta L, Boccardo F. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. Anticancer Res. 1995 Nov-Dec;15(6B):2687-90. PubMed PMID: 8669848.

340: Tatoud R, Degeorges A, Prévost G, Hoepffner JL, Gauvillé C, Millot G, Thomas F, Calvo F. Somatostatin receptors in prostate tissues and derived cell cultures, and the in vitro growth inhibitory effect of BIM-23014 analog. Mol Cell Endocrinol. 1995 Sep 22;113(2):195-204. PubMed PMID: 8674827.

341: Hofland LJ, Visser-Wisselaar HA, Lamberts SW. Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes. Biochem Pharmacol. 1995 Jul 31;50(3):287-97. Review. PubMed PMID: 7646531.

342: Anthony LB, May ME, Oates JA. Case report: lanreotide in the management of hypercalcemia of malignancy. Am J Med Sci. 1995 Jun;309(6):312-4. PubMed PMID: 7771500.

343: Tan CK, Podila PV, Taylor JE, Nagorney DM, Wiseman GA, Gores GJ, LaRusso NF. Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology. 1995 Jun;108(6):1908-16. PubMed PMID: 7768398.

344: Di Leo A, Ferrari L, Bajetta E, Bartoli C, Vicario G, Moglia D, Miceli R, Callegari M, Bono A. Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical Oncology. Breast Cancer Res Treat. 1995 Jun;34(3):237-44. PubMed PMID: 7579488.

345: Figg WD, Thibault A, Cooper MR, Reid R, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. Cancer. 1995 Apr 15;75(8):2159-64. PubMed PMID: 7535186.

346: Jonas S, John M, Boese-Landgraf J, Häring R, Prevost G, Thomas F, Rosewicz S, Riecken EO, Wiedenmann B, Neuhaus P. Somatostatin receptor subtypes in neuroendocrine tumor cell lines and tumor tissues. Langenbecks Arch Chir. 1995;380(2):90-5. PubMed PMID: 7760656.

347: Wen PY, Loeffler JS. Advances in the diagnosis and management of pituitary tumors. Curr Opin Oncol. 1995 Jan;7(1):56-62. Review. PubMed PMID: 7696364.

348: Maulard C, Richaud P, Droz JP, Jessueld D, Dufour-Esquerré F, Housset M. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol. 1995;36(3):259-62. PubMed PMID: 7540120.

349: Woltering EA, Barrie R, O'Dorisio TM, O'Dorisio MS, Nance R, Cook DM. Detection of occult gastrinomas with iodine 125-labeled lanreotide and intraoperative gamma detection. Surgery. 1994 Dec;116(6):1139-46; discussion 1146-7. PubMed PMID: 7985099.

350: Janson ET, Westlin JE, Eriksson B, Ahlström H, Nilsson S, Oberg K. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol. 1994 Dec;131(6):577-81. PubMed PMID: 7804439.

351: Morange I, De Boisvilliers F, Chanson P, Lucas B, DeWailly D, Catus F, Thomas F, Jaquet P. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab. 1994 Jul;79(1):145-51. PubMed PMID: 8027218.

352: Wolthers T, Grøfte T, Orskov H, Hamberg O, Foegh M, Vilstrup H. Effect of lanreotide, a somatostatin analogue, on urea synthesis in normal man. Clin Nutr. 1994 Apr;13(2):105-10. PubMed PMID: 16843368.

353: Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol (Oxf). 1994 Mar;40(3):421-8. PubMed PMID: 8187308.

354: Cotto C, Quoix E, Thomas F, Henane S, Trillet-Lenoir V. Phase I study of the somatostatin analogue somatuline in refractory small-cell lung carcinoma. Ann Oncol. 1994 Mar;5(3):290-1. PubMed PMID: 8186178.

355: Prévost G, Bourgeois Y, Mormont C, Lerrant Y, Veber N, Poupon MF, Thomas F. Characterization of somatostatin receptors and growth inhibition by the somatostatin analogue BIM23014 in small cell lung carcinoma xenograft: SCLC-6. Life Sci. 1994;55(2):155-62. PubMed PMID: 8015359.

356: Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Lamberts SW. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology. 1994 Jan;134(1):301-6. PubMed PMID: 7903931.

357: Scherübl H, Wiedenmann B, Riecken EO, Thomas F, Böhme E, Räth U. Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide. Eur J Cancer. 1994;30A(10):1590-1. PubMed PMID: 7833124.

358: Canobbio L, Cannata D, Miglietta L, Boccardo F. Somatuline and tamoxifen in postmenopausal breast cancer patients. Ann N Y Acad Sci. 1993 Nov 30;698:362-6. PubMed PMID: 8279776.

359: Weckbecker G, Raulf F, Stolz B, Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther. 1993 Nov;60(2):245-64. Review. PubMed PMID: 7912834.

360: Dörr U, Wurm K, Höring E, Guzman G, Räth U, Bihl H. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs. Horm Metab Res Suppl. 1993;27:36-43. PubMed PMID: 8330870.

361: Rieu M, Rosilio M, Richard A, Vannetzel JM, Kuhn JM. Paradoxical effect of somatostatin analogues on the ectopic secretion of corticotropin in two cases of small cell lung carcinoma. Horm Res. 1993;39(5-6):207-12. PubMed PMID: 8314205.

362: Prévost G, Provost P, Sallé V, Lanson M, Thomas F. A cross-linking assay allows the detection of receptors for the somatostatin analogue, lanreotide in human breast tumours. Eur J Cancer. 1993;29A(11):1589-92. PubMed PMID: 8105838.

363: Anthony L, Johnson D, Hande K, Shaff M, Winn S, Krozely M, Oates J. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol. 1993;32(2):217-23. PubMed PMID: 7686764.

364: Friess H, Kunz J, Büchler M. [Somatostatin analogs: a new therapeutic concept in pancreatic cancer?]. Z Gastroenterol. 1992 Nov;30(11):818-9. German. PubMed PMID: 1471391.

365: Sassolas G, Melmed S. Symposium: basic somatostatin research. Metabolism. 1992 Sep;41(9 Suppl 2):11-6. PubMed PMID: 1355583.

366: Canobbio L, Boccardo F, Cannata D, Gallotti P, Epis R. Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study. Cancer. 1992 Feb 1;69(3):648-50. PubMed PMID: 1346097.

367: Prévost G, Foehrlé E, Thomas F, Pihan I, Veber N, Starzec A, Israël L. Growth of human breast cancer cell lines is inhibited by the somatostatin analog BIM23014. Endocrinology. 1991 Jul;129(1):323-9. PubMed PMID: 2055192.